Momeni Ali Z, Aminjavaheri Malihalsadat
Aminjavaheri Medical Lab. P.O. Box 1191, 81465 Isfahan, Iran.
Eur J Dermatol. 2003 Jan-Feb;13(1):40-3.
Cutaneous leishmaniasis (CL) is endemic in many countries. It has been recognized as a major public health problem in Iran. The pentavalent antimonials are the first line drugs for the treatment of CL. Recently strains resistant to these drugs have been reported. Allopurinol (AL) has also been suggested for treatment of CL. The efficacy of combination of AL and meglumine antimoniate (MA) in treatment of non-healing cases of CL was evaluated. Non-healing cases of CL have been treated with combination of AL (20 mg/kg for 30 days) and meglumine antimoniate (60 mg/kg per day for 20 days). Twenty-six patients with lupoid leishmaniasis, 6 patients with chronic leishmaniasis and 5 patients who had unhealed leishmaniasis due to leishmanization were accepted for the study. All of the patients except two responded well to treatment, no side effects have been observed and a two year follow up showed no recurrence. A combination of AL and MA increase the antileishmanial effects of antimoniate. We suggest this combination therapy for non-healing and resistant cases of CL.
皮肤利什曼病（CL）在许多国家呈地方性流行。在伊朗，它已被视为一个主要的公共卫生问题。五价锑剂是治疗CL的一线药物。最近已有对这些药物耐药的菌株被报道。别嘌呤醇（AL）也被建议用于CL的治疗。评估了AL与葡甲胺锑（MA）联合治疗CL不愈合病例的疗效。CL不愈合病例采用AL（20mg/kg，共30天）与葡甲胺锑（60mg/kg/天，共20天）联合治疗。26例类狼疮性利什曼病患者、6例慢性利什曼病患者以及5例因利什曼化而未愈合的利什曼病患者被纳入该研究。除两名患者外，所有患者对治疗反应良好，未观察到副作用，两年随访显示无复发。AL与MA联合可增强锑剂的抗利什曼作用。我们建议将这种联合疗法用于CL的不愈合及耐药病例。
